Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an open-label, Phase I, dose-escalation study using a 3 + 3 design to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered QD. This study will include patients with locally advanced or metastatic solid tumors, NHL, or multiple myeloma (MM) (expansion stage only) for which standard therapy either does not exist or has proven ineffective or intolerable.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Imbedded metallic material/devices (metal implants or large tattoos in the field of view)
Severe claustrophobia
Physical characteristics (weight or size) that exceed the capabilities of the MRI scanner
Known allergy or hypersensitivity reactions to gadolinium, verse
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal